Patent number: 6414126
Abstract: SGLT2 inhibiting compounds are provided having the formula
where
R1, R2, and R2a are independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5i or halogen, or two of R1, R2 and R2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle;
R3 and R4 are independently hydrogen, OH, OR5a, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, —OCHF2, —OCF3, halogen, —CN, —CO2R5b, —CO2H, —COR6b, —CH(OH)R6c, —CH(OR5h)R6d, —CONR6R6a, —NHCOR5c, —NHSO2R5d, —NHSO2Aryl, Aryl, —SR5e, —SOR5f, —SO2R5g, —SO2Aryl, or a five, six or seven membered heterocycle, or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle;
R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h and R5i are independently lower alkyl;
R6, R6a, R6b, R6c and R6d are independently hydrogen, alkyl,
Type:
Grant
Filed:
October 4, 2000
Date of Patent:
July 2, 2002
Assignee:
Bristol-Myers Squibb Company
Inventors:
Bruce Ellsworth, William N. Washburn, Philip M. Sher, Gang Wu, Wei Meng